FIELD: medicine.
SUBSTANCE: present invention relates to a method for treating a patient with colorectal cancer and a method for predicting the therapeutic effect of chemotherapy using an antitumor agent containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5, in relation to a patient with colorectal cancer, comprising the following stages: (1) detecting the expression of TK1 protein by immunohistochemical staining in tumor cells contained in a biological sample obtained from a patient; (2) classifying tumor cells into positive cells and negative cells, taking into account the results of detection obtained at stage (1), and calculating the percentage of positive cells among the tumor cells; and (3) taking into account the results of the calculation obtained at stage (2), predicting that when the percentage is 30 % or more, the patient will respond to chemotherapy with an anticancer agent containing trifluridine and tipiracil hydrochloride in a 1:0.5 molar ratio.
EFFECT: invention provides chemotherapy with more significant effects of prolonged survival for patients with colorectal cancer (in particular, patients with colorectal cancer, resistant or not tolerating standard therapy, less responsive to antitumor agents and having a smaller choice of antitumor agents for meaningful prolongation of their survival).
4 cl, 1 ex, 2 tbl
